**Past Issues** 

Translate ▼



A PARTNERSHIP WITH THE CH.I.L.D FOUNDATION

### April 2023 Newsletter


#### **News & Reminders**

- We encourage CIDsCaNN members and trainees to develop research protocols, abstracts and publications using information from the <u>CIDsCaNN database</u>.
- Did you know? Conference travel funds are available for trainees and early-stage investigators who submit and present abstracts of CIDsCaNN data.

## **Current Projects**

Past Issues

Translate ▼



#### Phase 2 CIDsCaNN: AMBITION-CD

Assessment of Mucosal Biochemical and clinical response to Interleukin-12/23 or TNF Inhibitors in biologic-naïve Crohn's Disease

Inclusion criteria: Children age 2-17y with Crohn's disease starting first biologic as antiTNF or UST for luminal Crohn's disease

Participating sites: All

Target: 200 antiTNF, 100 UST

**AMBITION-CD Site Lead Meetings** take place the second Tuesday of each month.

We're currently developing two information sheets that will be useful for coordinators, Pls, and clinical staff:

The first is a **clinic information sheet** that clinicians can reference for inclusion/exclusion criteria and other study details including drug level and fecal calprotectin timing. These can be posted in clinic and circulated to staff.

The second is a **coordinator cheat sheet.** This onepage document is an overview of tasks and procedures for each time-point, including inclusion criteria and which CRFs to complete at each time point.

More information about these to come!

Contact: Hayley <a href="mailto:hayley.mckay@sickkids.ca">hayley.mckay@sickkids.ca</a>

Contact: Michelle michelle.ouzounis@sickkids.ca

Subscribe Past Issues Translate ▼

	Date)
Biopsies	40 (42%)
DNA	59 (61%)
RNA	67 (70%)
Serum	68 (71%)
Stool	44 (46%)

Site	Enrolled in AMBITION-CD	Biologic	
		Ustekinumab	Anti TNF
Calgary	3	2	1
Ottawa	5	0	5
Montreal	1	1	0
Vancouver	1	0	1
Toronto	39	11	28
London	10	2	8
Edmonton	16	10	6
Halifax	5	2	3
St Johns	2	1	1
Winnipeg	12	2	10
Total	94	31	63

### **Ongoing Follow-up of Inception Cohort Study**

• Inclusion criteria: Children age 2-17y with IBD

### **Dual biologics** (via Main Prevalent Cohort Study)

• Inclusion criteria: Children age 2-17y with IBD on 2 concurrent biologics

• Participating sites: All

• Contact: Wael welmatary@exchange.hsc.mb.ca

### Predictors of response to anti-TNF therapy (Biomark study)

Subscribe Past Issues Translate ▼

Target: 75

Participating sites: Toronto, Ottawa, Halifax

• Contact: Amanda Amanda.ricciuto@sickkids.ca

Contact: Shantel <u>Shantel.mangroo@sickkids.ca</u>

# Implementing a Multimodal Intervention to Improve the Transition of Patients with Inflammatory Bowel Disease from Pediatric to Adult Care

Inclusion criteria: Aged 16-17.5 y with IBD, ability to provide informed consent, ability
to speak/read English at a Grade 8 level, intention to reside in Canada after transfer to
adult care, access to smartphone/computer (can be purchased for the participant if this
is a barrier to participation)

• Target: 115

Participating sites: Toronto, Ottawa, McMaster, BCCH

• Contact: Eric eric.benchimol@sickkids.ca

## **Education Update**

#### Most recent session:

April 25, 2023 — Session 7: Quality Improvement in IBD

#### Up-coming sessions:

June 13, 2023 — **Session 8: TBA** — 3-4:30pm EST

November 14, 2023- Session 9: Transition from Pediatric to Adult Care in IBD: What Can CIDsCaNN Do TO Improve Care? - 3-4:30pm EST

Please respond to the Education Committees new survey about future topics!

We take your topic suggestions very seriously, you may see one of your topic ideas show up in June of 2023 or during another future session. Thank you very much for your ongoing engagement and ideas!

Missed a past session? No problem! Listen to recordings at cidscann.ca/education

Subscribe Past Issues Translate ▼

### Learn more & register

We encourage you to share the Education Session calendar invites with your multidisciplinary teams. Please find the dates for future sessions, and past recordings at <a href="cidscann.ca/education">cidscann.ca/education</a>



### Publications, Awards & Grants

Congratulations to Eric Benchimol, the new **Editor in Chief** at the *Journal of the Canadian Association of Gastroenterology (JCAG).* 

A Comparison of Preference-Based, Generic and Disease-Specific Health-Related Quality of Life in Pediatric Inflammatory Bowel Disease has been published by Naaz Bashir, Wendy Ungar, Thomas Walters, Anne Griffiths, Anthony Otley and Jeff Critch in the April issue of JCAG.

**Past Issues** 

Translate ▼



Pediatric Gastroenterologist, Sainte Justine University Hospital, Montreal

We're pleased to announce the appointment of Kelly to Co-chair of the Patient Engagement Committee, alongside Dr. Tony Otley.

Kelly believes strongly in advocating for patients with IBD for access to new medications, mental health care and better resources.

"One of my objectives is to implement the iPeer2Peer program in Frenchspeaking Quebec and maybe (fingers crossed), make it accessible to all Canadian teens living with IBD," Kelly says.

When not working, you can find Kelly skiing (on water and snow), travelling, and hanging with her two little guys.

### Join us in welcoming these new CIDsCaNN members!

Jasbir Dhaliwal – Individual membership Trained at SickKids and is currently Assistant Professor at University of Cincinnati

Brigitte Moreau – Individual membership Associate Professor at Sherbrooke University

Alexandra Hudson – Trainee membership Trainee at Stollery Children's Hospital, Edmonton

Past Issues

Translate >

# Inank you for your engagement ∞ contribution to CIDsCaNN!



Copyright © 2022 Canadian Children Inflammatory Bowel Disease Network, All rights reserved.

### Our mailing address is:

555 University Avenue, Toronto ON Canada M5G 1X8

email: info@cidscann.ca

Want to change how you receive these emails?

You can update your preferences or unsubscribe from this list.

